

Supporting Information

for

**Efficient synthesis of dihydropyrimidinones via
a three-component Biginelli-type reaction of
urea, alkylaldehyde and arylaldehyde**

Haijun Qu, Xuejian Li, Fan Mo, and Xufeng Lin*

Address: Department of Chemistry, Zhejiang University, Hangzhou 310027,
China

Email: Xufeng Lin - lxfok@zju.edu.cn

* Corresponding author

Experimental details and spectroscopic data

Contents

General information.....	S2
General procedure.....	S2
Characterization data.....	S3
NMR spectra.....	S6
HPLC spectra	S28

General information

Melting points were obtained on a microscopical instrument and are uncorrected. NMR spectra were recorded on a 400 MHz spectrometer and TMS as internal standard. IR spectra were recorded on a FTIR spectrometer. HRMS data were obtained using EI ionization. All reagents and solvents used were commercially available. Column chromatography was carried out on silica gel column (300-400 mesh) with mixed solvents (hexane/ethyl acetate). Optical rotations were determined using a Perkin Elmer Model 341 polarimeter at 20 °C. The enantiomeric excesses (ee) were determined by chiral HPLC analysis on a Daicel Chiraldapak AD-H column.

General procedure for the iodine-catalyzed synthesis of DHPMs 4

Mono-substituted urea **1** (2.5 mmol), aromatic aldehyde **3** (3.75 mmol) and iodine (0.25 mmol) were dissolved in 3 mL acetonitrile under nitrogen atmosphere. After the mixture was stirred at room temperature for 10 minutes, alkylaldehyde **2** (2.5 mmol) was added, and the resulting mixture was stirred under reflux for 12 hours. Then the reaction mixture was diluted with ethyl acetate, and washed with a solution of sodium thiosulfate followed by water. The organic phase was dried over anhydrous Na₂SO₄, and evaporation of the solvent followed by purification on silica gel afforded the pure desired DHPM **4**.

General procedure for the catalytic asymmetric synthesis of DHPMs 4.

Mono-substituted urea **1** (0.2 mmol), aromatic aldehyde **3** (0.3 mmol), MS 4 Å (0.1 g) and **5a** (0.02 mmol) were dissolved in 1 mL toluene under nitrogen atmosphere. After the mixture was stirred at room temperature for 30 minutes, alkyl aldehyde **2** (0.2 mmol) was added, and the resulting mixture was stirred at room temperature for 2 days. Then the reaction mixture was purified by flash chromatography on silica gel to afford the pure desired chiral DHPM **4**.

Characterization data

1-Methyl-4-(4-nitrophenyl)-5-phenyl-3,4-dihydropyrimidin-2(1H)-one (4a). Yellow solid, m.p.186-188 °C; the chiral material was determined to be of 77% ee by chiral HPLC analysis [Daicel Chiraldak AD-H, *n*-hexane / *i*-propanol = 80/20, 1.0 mL/min, λ = 254 nm, t (major) = 16.60 min, t (minor) = 22.42 min]. $[\alpha]_D^{20}$ = + 5.6° (c = 0.52, CHCl₃). IR(neat) ν 3250, 1682, 1651, 1519, 1497, 1455, 1403, 1270, 818, 736, 732, 700 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ = 8.13 (d, J = 8.7 Hz, 2 H), 7.46 (d, J = 8.7 Hz, 2 H), 7.26-7.12 (m, 5 H), 6.55 (s, 1 H), 6.14 (s, 1 H), 5.60 (d, J = 2.6 Hz, 1 H), 3.20 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ = 153.24, 149.21, 147.53, 135.30, 128.78, 127.95, 127.65, 127.06, 124.86, 124.21, 112.81, 57.34, 34.79 ppm. HRMS (EI): m/z calcd for (C₁₇H₁₅N₃O₃): 309.1113; found: 309.1111.

1-Methyl-4-(3-nitrophenyl)-5-phenyl-3,4-dihydropyrimidin-2(1H)-one (4b). Yellow solid, m.p.180-182 °C; the chiral material was determined to be of 75% ee by chiral HPLC analysis [Daicel Chiraldak AD-H, *n*-hexane / *i*-propanol = 80/20, 1.0 mL/min, λ = 254 nm, t (major) = 14.72 min, t (minor) = 21.31 min]. $[\alpha]_D^{20}$ = +8.2° (c = 0.46, CHCl₃). IR (neat) ν 3239, 3084, 2928, 1681, 1599, 1497, 1456, 1404, 1349, 1270, 759, 737, 693, 596 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ = 8.16 (s, 1 H), 8.08 (d, J = 8.2 Hz, 1 H), 7.63 (d, J = 7.7 Hz, 1 H), 7.45 (t, J = 7.9 Hz, 1 H), 7.26 (s, 1 H), 7.22 (s, 1 H), 7.16 (t, J = 6.6 Hz, 3 H), 6.63 (s, 1 H), 6.28 (s, 1 H), 5.60 (d, J = 2.5 Hz, 1 H), 3.23 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ = 153.41, 148.48, 144.36, 135.27, 132.8, 129.84, 128.76, 128.22, 126.93, 124.63, 122.02, 112.39, 56.96, 34.79 ppm. HRMS (EI): m/z calcd for (C₁₇H₁₅N₃O₃): 309.1113; found: 309.1112.

4-(1-Methyl-2-oxo-5-phenyl-1,2,3,4-tetrahydropyrimidin-4-yl)benzonitrile (4c). White solid, m.p. 113-115 °C; the chiral material was determined to be of 64% ee by chiral HPLC analysis [Daicel Chiraldak AD-H, *n*-hexane / *i*-propanol = 80/20, 1.0 mL/min, λ = 254 nm, t (major) = 16.34 min, t (minor) = 26.66 min]. $[\alpha]_D^{20}$ = +4.8° (c = 0.41, CHCl₃); IR(neat) ν 3249, 2925, 2228, 1679, 1603, 1498, 1456, 1404, 1327, 1269, 1108, 765, 731, 694, 587 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, J = 7.2 Hz, 2 H), 7.38 (d, J = 7.9 Hz, 2 H), 7.26-7.19 (m, 2 H), 7.14 (dd, J = 17.6, 7.4 Hz, 3 H), 6.53 (s, 1 H), 6.08 (br, 1 H), 5.52 (s, 1 H), 3.17 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 153.26, 147.33, 135.37, 132.72, 128.72, 127.90, 127.47, 126.96, 124.81, 118.44, 112.77, 111.83, 57.50, 34.72 ppm. HRMS (EI): m/z calcd for (C₁₈H₁₅N₃O): 289.1215; found: 289.1225.

4-(4-Chlorophenyl)-1-methyl-5-phenyl-3,4-dihydropyrimidin-2(1H)-one (4d). White solid ,m.p: 149-151°C; the chiral material was determined to be of 32% ee by chiral HPLC analysis [Daicel Chiraldak AD-H, *n*-hexane / *i*-propanol = 90/10,0.8 mL/min, λ = 254 nm, t (major) = 29.13min, t (minor) = 31.84 min]. IR (neat) ν 3108, 1671, 1647, 1593, 1526, 1491, 1462, 1401, 1328, 726, 700 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ = 7.21 (m, 9 H), 6.53 (s, 1 H), 5.51 (s, 1 H), 5.44 (d, J = 2.1 Hz, 1 H), 3.19 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ =140.88, 135.67, 133.68, 129.02, 128.57, 128.13, 127.48, 126.70, 124.81, 124.81, 113.30, 57.32, 34.69 ppm. HRMS (EI): m/z calcd for (C₁₇H₁₅ClN₂O): 298.0873; found: 298.0870.

4-(4-Bromophenyl)-1-methyl-5-phenyl-3,4-dihydropyrimidin-2(1H)-one (4e). White solid, m.p. 170-172 °C; the chiral material was determined to be of 53% ee by chiral HPLC analysis [Daicel Chiraldak AD-H, *n*-hexane / *i*-propanol = 80/20, 1.0 mL/min, λ = 254 nm, t (major) = 13.68 min, t (minor) = 18.87 min]. $[\alpha]_D^{20}$ = +3° (c = 0.44, CHCl₃). IR(neat) ν 3265, 1673, 1485, 1455, 1405, 1325, 1266, 1003, 754, 730, 694 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ =7.41 (d, J = 8.3 Hz, 2 H), 7.25-7.19 (m, 2 H), 7.15 (t, J = 7.8 Hz, 5 H), 6.52 (s, 1 H), 5.56 (s, 1 H), 5.43 (d, J = 2.1 Hz, 1 H), 3.19 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ =153.29, 141.39, 135.71, 132.00, 128.59, 128.47, 127.51, 126.75, 124.85, 121.93, 113.30, 57.46, 34.69 ppm. HRMS (EI): m/z calcd for (C₁₇H₁₅BrN₂O): 342.0368; found: 340.0211.

4-(2-Bromophenyl)-1-methyl-5-phenyl-3,4-dihydropyrimidin-2(1H)-one (4f). White solid, m.p: 173-175°C; the chiral material was determined to be of 20% ee by chiral HPLC analysis [Daicel Chiraldak AD-H, *n*-hexane / *i*-propanol = 90/10, 0.8 mL/min, λ = 254 nm, t (major) = 29.30 min, t (minor) = 31.37min]. IR (neat) ν 3242, 3080, 2923, 2238, 1678, 1597, 1496, 1470, 1402, 1325, 1262, 1185, 1111, 757, 730, 695, 599 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ =7.46 (s, 1 H), 7.39 (d, J = 7.8 Hz, 1 H), 7.23 (m, 3 H), 7.17 (m, 4 H), 6.58 (s, 1 H), 5.52 (s, 1 H), 5.43 (d, J = 2.3 Hz, 1 H), 3.23 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ =153.14, 144.57, 135.65, 131.17, 130.51, 129.87, 128.60, 127.78, 126.73, 125.41, 124.77, 122.99, 112.83, 57.58, 34.76 ppm. HRMS (EI): m/z calcd for (C₁₇H₁₅BrN₂O): 342.0368; found: 340.0207.

1-Methyl-5-phenyl-4-(4-(trifluoromethyl)phenyl)-3,4-dihydropyrimidin-2(1H)-one (4g). White solid, m.p. 130-132 °C; IR(neat) ν 3318, 1663, 1598, 1496, 1451, 1406, 1324, 1167, 1125, 1067, 1009, 855, 730, 691 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ = 7.55 (d, J = 8.2 Hz, 2 H), 7.41 (d, J = 8.1 Hz, 2 H), 7.26-7.21 (m, 2 H), 7.17 (t, J = 6.7 Hz, 3 H), 6.56 (s, 1 H), 5.67 (s, 1 H), 5.54 (d, J = 2.4 Hz, 1 H), 3.21 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ =153.31, 146.15, 135.61, 130.20 (J =33 Hz), 128.70, 127.77, 126.88, 125.98 (J =229 Hz), 125.97, 125.93, 125.27, 113.14, 57.59, 34.74 ppm. HRMS (EI): m/z calcd for (C₁₈H₁₅F₃N₂O): 332.1136; found: 332.1138.

1-Methyl-4,5-diphenyl-3,4-dihydropyrimidin-2(1H)-one (4h). White solid, m.p. 179-181 °C; IR (neat) ν 3319, 1681, 1651, 1599, 1495, 1454, 1403, 1326, 1269, 754, 732, 697, 595 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ = 7.33-7.14 (m, 10 H), 6.55 (s, 1 H), 5.44 (d, *J* = 2.2 Hz, 1 H), 5.31 (s, 1 H), 3.20 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ = 153.26, 142.37, 136.05, 128.93, 128.48, 128.04, 127.38, 126.70, 126.55, 124.88, 113.60, 58.22, 34.68 ppm. HRMS (EI): m/z calcd for (C₁₇H₁₆N₂O): 264.1263; found: 264.1264.

*Methyl-5-phenyl-4-(*p*-tolyl)-3,4-dihydropyrimidin-2(1H)-one (4i).* White solid, m.p. 158-160 °C; IR (neat) ν 3247, 3058, 2920, 1678, 1496, 1455, 1402, 1328, 1271, 1105, 1048, 751, 682, 593 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ = 7.24-7.05 (m, 9 H), 6.53 (s, 1 H), 5.40 (d, *J* = 2.0 Hz, 1 H), 5.29 (s, 1 H), 3.19 (s, 3 H), 2.28 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ = 153.29, 139.50, 137.73, 136.13, 129.58, 128.45, 127.26, 126.60, 126.48, 124.84, 113.71, 57.89, 34.66, 21.04 ppm. HRMS (EI): m/z calcd for (C₁₇H₁₈N₂O₂): 278.1419; found: 278.1418.

4-(4-Methoxyphenyl)-1-methyl-5-phenyl-3,4-dihydropyrimidin-2(1H)-one (4j). White solid, m.p: 168-170°C; the chiral material was determined to be of 33% ee by chiral HPLC analysis [Daicel Chiraldak AD-H, *n*-hexane / *i*-propanol = 90/10, 0.8 mL/min, λ = 254 nm, t (major) = 43.37 min, t (minor) = 48.50 min]; IR (neat) ν 3248, 1681, 1607, 1509, 1455, 1403, 1326, 1251, 1174, 752 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.19 (m, 4 H), 7.16 (m, 3 H), 6.81 (d, *J* = 8.6 Hz, 2 H), 6.53 (s, 1 H), 5.39 (d, *J* = 2.1 Hz, 1 H), 5.27 (s, 1 H), 3.76 (s, 3 H), 3.20 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 159.30, 153.21, 136.13, 134.71, 128.46, 127.94, 127.19, 126.51, 124.87, 114.25, 113.81, 57.68, 55.17, 34.67 ppm. HRMS(EI): m/z calcd for (C₁₈H₁₈N₂O₂): 294.1368; found: 294.1369.

*4-(Benzo[*d*][1,3]dioxol-5-yl)-1-methyl-5-phenyl-3,4-dihydropyrimidin-2(1H)-one (4k).* White solid, m.p. 202-204 °C; IR(neat) ν 3319, 2917, 1675, 1590, 1499, 1486, 1399, 1334, 1246, 1108, 1033, 685, 593 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.13 (m, 5 H), 6.84-6.68 (m, 3 H), 6.56 (s, 1 H), 5.92 (s, 2 H), 5.37 (d, *J* = 1.9 Hz, 1 H), 5.28 (s, 1 H), 3.22 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 153.13, 148.21, 147.38, 136.54, 135.95, 128.50, 127.35, 126.58, 124.79, 120.19, 113.52, 108.35, 107.11, 101.08), 58.00, 34.69 (s) ppm. HRMS (EI): m/z calcd for (C₁₈H₁₆N₂O₃): 308.1161; found: 308.1165.

1-Methyl-4-(naphthalen-1-yl)-5-phenyl-3,4-dihydropyrimidin-2(1H)-one (4l). White solid, m.p. 162-164 °C; IR (neat) ν 3238, 3059, 2925, 1678, 1598, 1497, 1455, 1403, 1327, 1266, 95, 780, 731, 694 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, *J* = 8.4 Hz, 1 H), 7.91 (d, *J* = 8.1 Hz, 1 H), 7.79 (d, *J* = 8.2 Hz, 1 H), 7.61 (t, *J* = 7.6 Hz, 1 H), 7.53 (m, 2H), 7.38 (t, *J* = 7.7 Hz, 1 H), 7.18 – 7.07 (m, 5 H), 6.84 (s, 1 H), 6.28 (d, *J* = 1.7 Hz, 1 H), 5.34 (s, 1 H), 3.23 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 153.17, 135.84, 135.79, 134.41, 130.25, 129.37, 128.83, 128.49, 128.40, 126.92, 126.48, 125.78, 125.09, 124.37, 121.77, 112.11, 53.62, 34.76 ppm. HRMS (EI): m/z calcd for (C₂₁H₁₈N₂O): 314.1419; found: 314.1419.

4-(Furan-2-yl)-1-methyl-5-phenyl-3,4-dihydropyrimidin-2(1H)-one (4m). White solid, m.p. 161-163 °C; IR (neat) ν 3241, 2921, 1678, 1599, 1497, 1455, 1403, 1326, 1250, 1108, 1000, 780, 748, 694, 593 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.36 (s, 1 H), 7.30 (d, *J* = 7.8 Hz, 1 H), 7.26 (t, *J* = 5.9 Hz, 3 H), 7.20 (t, *J* = 6.9 Hz, 1 H), 6.61 (s, 1 H), 6.27 (s, 1 H), 6.16 (d, *J* = 2.5 Hz, 1 H), 5.48 (s, 1 H), 5.39 (s, 1 H), 3.21 (s, 3 H) ppm . ¹³C NMR (100 MHz, CDCl₃) δ 154.17, 153.66, 142.55, 135.61, 128.60, 128.09, 126.66, 124.35, 111.13, 110.38, 106.94, 51.08, 34.77 ppm. HRMS (EI): m/z calcd for (C₁₅H₁₄N₂O₂): 254.1055; found: 254.1051.

4-Benzyl-1-methyl-5-phenyl-3,4-dihydropyrimidin-2(1H)-one (4n). White solid, m.p. 91-93 °C; IR (neat) ν 3238, 1681, 1599, 1495, 1454, 1408, 132, 1269, 752, 698 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.33 (m, 4 H), 7.31 (t, *J* = 7.3 Hz, 2 H), 7.25 (t, *J* = 6.9 Hz, 2 H), 7.17 (d, *J* = 7.3 Hz, 2 H), 6.32 (s, 1 H), 5.15 (s, 1 H), 4.66 (d, *J* = 8.4 Hz, 1 H), 3.00 (s, 3 H), 2.90 (m, 1 H), 2.77-2.66 (m, 1 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 153.97, 136.63, 135.85, 129.64, 128.88, 128.44, 127.16, 126.72, 126.67, 124.50, 114.11, 55.21, 42.41, 34.37 ppm ; HRMS (EI): m/z calcd for (C₁₈H₁₈N₂O): 278.1419; found: 278.1418.

5-Isopropyl-1-methyl-4-(4-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one (4o). Yellow liquid, IR (neat) ν 3249, 2940, 1678, 1521, 1462, 1341, 1262, 1113, 858, 688 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, *J* = 8.6 Hz, 2 H), 7.46 (d, *J* = 8.6 Hz, 2 H), 5.86 (s, 1 H), 5.56 (s, 1 H), 5.08 (d, *J* = 1.9 Hz, 1 H), 3.10 (s, 3 H), 1.95 (m, 1 H), 1.00 (d, *J* = 6.8 Hz, 3 H), 0.95 (d, *J* = 7.0 Hz, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 153.20, 150.19, 147.67, 127.87, 124.28, 124.16, 119.07, 58.06, 34.45, 28.43, 21.98, 20.73 ppm. HRMS (EI): m/z calcd for (C₁₄H₁₇N₃O₃): 275.1270; found: 275.1269.

5-Butyl-1-methyl-4-(4-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one (4p). Yellow solid, m.p. 121-123 °C; IR (neat) ν 3258, 2956, 2929, 2869, 1673, 1596, 1520, 1465, 1396, 1346, 1310, 1268, 1108, 1036, 855, 754, 697 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 8.6 Hz, 2 H), 7.45 (d, *J* = 8.6 Hz, 2 H), 5.80 (s, 1 H), 5.37 (s, 1 H), 5.02 (s, 1 H), 3.07 (s, 3 H), 1.72 (d, *J* = 4.5 Hz, 2 H), 1.35-1.18 (m, 4 H), 0.83 (t, *J* = 6.9 Hz, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 153.20, 149.87, 147.61, 127.81, 125.17, 124.05, 112.71, 58.95, 34.27, 29.88, 29.14, 22.10, 13.74 ppm. HRMS (EI): m/z calcd for (C₁₅H₁₉N₃O₃): 289.1426; found: 289.1421.

1-Methyl-4-(4-nitrophenyl)-5-pentyl-3,4-dihydropyrimidin-2(1H)-one (4q). Yellow solid, m.p. 127-129 °C; IR (neat) ν 3259, 295, 2867, 1674, 1520, 1466, 1346, 1268, 1110, 854, 753, 697 cm⁻¹; ¹H NMR (400 MHz,

CDCl_3) δ 8.21 (d, J = 8.6 Hz, 2 H), 7.47 (d, J = 8.6 Hz, 2 H), 5.83 (s, 1 H), 5.31 (s, 1 H), 5.04 (s, 1 H), 3.09 (s, 3 H), 1.72 (t, 2 H), 1.32-1.15 (m, 6 H), 0.86 (t, J = 6.8 Hz, 3 H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 153.13, 149.85, 147.67, 127.83, 125.19, 124.09, 112.76, 59.07, 34.31, 31.21, 30.18, 26.70, 22.34, 13.90 ppm. HRMS (EI): m/z calcd for ($\text{C}_{16}\text{H}_{21}\text{N}_3\text{O}_3$): 303.1583; found: 303.1583.

*1-Ethyl-4-(4-nitrophenyl)-5-phenyl-3,4-dihydropyrimidin-2(1*H*)-one (4r).* Yellow solid, m.p. 182-184 °C; the chiral material was determined to be of 32% ee by chiral HPLC analysis [Daicel Chiraldak AD-H, *n*-hexane / *i*-propanol = 80/20, 0.8 mL/min, λ = 254 nm, t (major) = 28.16 min, t (minor) = 37.97 min]. $[\alpha]_D^{20} = +14.8^\circ$; (c = 0.36, CHCl_3); IR (neat) ν 3299, 2932, 1678, 1598, 1520, 1497, 1453, 1347, 1271, 1236, 1121, 817, 757, 731, 699 cm⁻¹; ^1H NMR (400 MHz, CDCl_3) δ 8.14 (d, J = 8.4 Hz, 2 H), 7.46 (d, J = 8.4 Hz, 2 H), 7.24 (d, J = 7.4 Hz, 2 H), 7.17 (m, 3 H), 6.58 (s, 1 H), 5.97 (s, 1 H), 5.58 (s, 1 H), 3.63 (m, 2 H), 1.27 (t, J = 7.1 Hz, 3 H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 152.75, 149.32, 147.49, 135.46, 128.75, 127.61, 126.99, 126.53, 124.80, 113.05, 57.12, 42.17, 14.43 ppm. HRMS (EI): m/z calcd for ($\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_3$): 323.1270; found: 323.1270.

*1-Ethyl-4-(3-nitrophenyl)-5-phenyl-3,4-dihydropyrimidin-2(1*H*)-one (4s).* Light yellow solid, m.p. 150-152 °C; IR (neat) ν 3226, 3083, 2932, 1678, 1599, 1529, 1497, 1453, 1424, 1349, 1269, 1235, 1122, 1083, 909, 803, 758, 736, 693, 593 cm⁻¹; ^1H NMR (400 MHz, CDCl_3) δ 8.17 (s, 1 H), 8.09 (d, J = 8.2 Hz, 1 H), 7.63 (d, J = 7.7 Hz, 1 H), 7.30-7.20 (m, 1 H), 7.23 (d, J = 7.2 Hz, 2 H), 7.21-7.12 (m, 3 H), 6.66 (s, 1 H), 6.11 (s, 1 H), 5.57 (d, J = 2.5 Hz, 1 H), 3.78-3.53 (m, 2 H), 1.29 (t, J = 7.1 Hz, 3 H) ppm. ^{13}C NMR (101 MHz, CDCl_3) δ 152.72, 148.57, 144.47, 135.41, 132.86, 129.91, 128.76, 126.93, 126.76, 124.64, 123.02, 121.91, 112.88, 77.32, 77.00, 76.68, 57.01, 42.23, 14.45 ppm. HRMS (EI): m/z calcd for ($\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_3$): 323.1270; found: 323.1273.


4-(1-Ethyl-2-oxo-5-phenyl-1,2,3,4-tetrahydropyrimidin-4-yl)benzonitrile (4t). White solid, m.p. 209-211 °C; IR (neat) ν 3241, 3083, 2976, 2933, 2228, 1681, 1603, 1498, 1454, 1372, 1270, 1236, 1180, 1122, 909, 851, 803, 765, 732, 695, 592, 554 cm⁻¹; ^1H NMR (400 MHz, CDCl_3) δ 7.59 (d, J = 7.8 Hz, 2 H), 7.40 (d, J = 7.9 Hz, 2 H), 7.24 (d, J = 7.7 Hz, 2 H), 7.17 (m, 3 H), 6.57 (s, 1 H), 5.52 (s, 1 H), 5.46 (s, 1 H), 3.73 – 3.54 (m, 2 H), 1.27 (t, J = 6.7 Hz, 3 H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 152.76, 147.41, 135.49, 132.70, 128.69, 127.44, 126.90, 126.46, 124.74, 118.45, 112.99, 111.75, 57.30, 42.11, 14.39 ppm. HRMS (EI): m/z calcd for ($\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}$): 303.1372; found: 303.1370.


*4-(4-Chlorophenyl)-1-ethyl-5-phenyl-3,4-dihydropyrimidin-2(1*H*)-one (4u).* White solid, m.p. 191-193 °C; IR (neat) ν 3223, 3082, 2931, 1673, 1598, 1485, 1452, 1427, 1370, 1267, 1235, 1121, 1071, 1010, 907, 801, 756, 731, 693, 593 cm⁻¹; ^1H NMR (400 MHz, CDCl_3) δ 7.25 (m, 5 H), 7.22-7.13 (m, 4 H), 6.56 (s, 1 H), 5.76 (s, 1 H), 5.42 (s, 1 H), 3.61 (m, 2 H), 1.26 (t, J = 7.1 Hz, 3 H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 152.84, 140.95, 135.88, 133.74, 129.07, 128.58, 128.10, 126.72, 126.05, 124.82, 113.66, 57.26, 42.09, 14.43 ppm. HRMS (EI): m/z calcd for ($\text{C}_{18}\text{H}_{17}\text{ClN}_2\text{O}$): 312.1029; found: 312.1029.


*4-(4-Bromophenyl)-1-ethyl-5-phenyl-3,4-dihydropyrimidin-2(1*H*)-one (4v).* White solid, m.p. 189-191 °C; IR(neat) ν 3227, 2973, 1676, 1597, 1489, 1452, 1371, 1267, 1235, 1121, 1089, 1014, 907, 802, 757, 730, 694, 594 cm⁻¹; ^1H NMR (400 MHz, CDCl_3) δ 7.40 (d, J = 8.3 Hz, 2 H), 7.25-7.20 (m, 2 H), 7.15 (m, 5 H), 5.63 (s, 1 H), 5.40 (d, J = 2.3 Hz, 1 H), 3.74 -3.51 (m, 2 H), 1.26 (t, J = 7.1 Hz, 3 H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 152.66, 141.50, 135.90, 132.02, 128.58, 128.44, 126.70, 126.13, 124.81, 121.90, 113.50, 57.37, 42.08, 14.44 ppm. HRMS (EI): m/z calcd for ($\text{C}_{18}\text{H}_{17}\text{BrN}_2\text{O}$): 356.0524; found: 356.0524.


NMR spectra for compounds 4a-v














































4o





4o























HPLC spectra



4a


77% ee. [Daicel Chiralpak AD-H, *n*-hexane / isopropanol = 80 / 20, 1.0 mL/min, $\lambda = 254$ nm]







4b

75% ee. [Daicel Chiralpak AD-H, *n*-hexane / isopropanol = 80 / 20, 1.0 mL/min, λ = 254 nm]






Totals : 6.55606e4 1122.86163






64% ee. [Daicel Chiralpak AD-H, *n*-hexane / isopropanol = 80 / 20, 1.0 mL/min, λ = 254 nm]





4d

32% ee by chiral HPLC analysis [Daicel Chiralpak AD-H, *n*-hexane / isopropanol = 90/10,0.8 mL/min, λ = 254 nm, *t* (major) = 29.13min, *t* (minor) = 31.84 min].




```
=====
 面积百分比报告
=====
排序 : 信号
乘积因子 : 1.0000
稀释因子 : 1.0000
内标使用乘积因子和稀释因子
```

信号 1: VWD1 A, Wavelength=254 nm

#	保留时间 [min]	类型	峰宽 [min]	峰面积 mAU	*s	峰高 [mAU]	峰面积 %
1	29.128	MM	1.1421	4043.67993		59.01037	49.6929
2	31.687	MM	1.3107	4093.66016		52.05369	50.3071

总量 : 8137.34009 111.06406




```
=====
 面积百分比报告
=====
排序 : 信号
乘积因子 : 1.0000
稀释因子 : 1.0000
内标使用乘积因子和稀释因子
```



信号 1: VWD1 A, Wavelength=254 nm


#	保留时间 [min]	类型	峰宽 [min]	峰面积 mAU	*s	峰高 [mAU]	峰面积 %
1	29.351	UV	0.8643	397.15692		5.43445	33.8463
2	31.828	UV	1.0489	776.25714		9.08826	66.1537

总量 : 1173.41406 14.52271




53% ee. [Daicel Chiraldak AD-H, *n*-hexane / isopropanol = 80 / 20, 1.0 mL/min, λ = 254 nm]





4f

20% ee by chiral HPLC analysis [Daicel Chiraldak AD-H, *n*-hexane / isopropanol = 90/10, 0.8 mL/min, λ = 254 nm, *t* (major) = 29.30 min, *t* (minor) = 31.37 min].




```
=====
面积百分比报告
=====
排序 : 信号
乘积因子 : 1.0000
稀释因子 : 1.0000
内标使用乘积因子和稀释因子

信号 1: VWD1 A, Wavelength=254 nm

峰 保留时间 类型 峰宽 峰面积 *s 峰高 峰面积 %
# [min] [min] mAU *s [mAU] % [mAU]
-----|-----|-----|-----|-----|-----|-----|
1 29.295 MM 1.1731 939.65710 13.34975 49.6292
2 31.382 MM 1.2570 953.69946 12.64469 50.3708

总量 : 1893.35657 25.99444
```




```
=====
面积百分比报告
=====
排序 : 信号
乘积因子 : 1.0000
稀释因子 : 1.0000
内标使用乘积因子和稀释因子

信号 1: VWD1 A, Wavelength=254 nm


峰 保留时间 类型 峰宽 峰面积 *s 峰高 峰面积 %
# [min] [min] mAU *s [mAU] % [mAU]
-----|-----|-----|-----|-----|-----|-----|
1 29.062 MM 1.1321 786.20575 11.57461 60.0058
2 31.197 MM 1.2169 524.00977 7.17682 39.9942

总量 : 1310.21552 18.75143
```



4j


33% ee by chiral HPLC analysis [Daicel Chiralpak AD-H, *n*-hexane / isopropanol = 90/10, 0.8 mL/min, λ = 254 nm, *t* (major) = 43.37 min, *t* (minor) = 48.50 min]



```
=====
面积百分比报告
=====
序号 : 信号
乘积因子 : 1.0000
稀释因子 : 1.0000
内标使用乘积因子和稀释因子

信号 1: VWD1 A, Wavelength=220 nm
峰 保留时间 类型 峰宽 *s 峰面积 [mAU] 峰高 [mAU] 峰面积 *
# [min] [min] [min] *s [mAU] [mAU] *
1 40.985 MM 2.3898 5.1645e4 360.18765 50.4564
2 45.825 MM 2.9569 5.07123e4 285.83899 49.5436


总量 : 1.02359e5 646.02664
```



```
=====
面积百分比报告
=====
序号 : 信号
乘积因子 : 1.0000
稀释因子 : 1.0000
内标使用乘积因子和稀释因子

信号 1: VWD1 A, Wavelength=220 nm
峰 保留时间 类型 峰宽 *s 峰面积 [mAU] 峰高 [mAU] 峰面积 *
# [min] [min] [min] *s [mAU] [mAU] *
1 43.379 MM 2.5333 2659.10962 17.49437 36.4372
2 48.509 MM 3.3599 4638.67139 23.01027 63.5628

总量 : 7297.78101 40.50464
```



32% ee. [Daicel Chiralpak AS-H, *n*-hexane / isopropanol = 80 / 20, 0.8 mL/min, λ = 254 nm]

